Halozyme Announces Resumption of Patient Enrollment, Dosing in PEGPH20 Clinical Trial
July 22, 2014 at 09:02 AM EDT
Halozyme Therapeutics, Inc. (NASDAQ: HALO) today announced that it has resumed enrollment and dosing of patients in its ongoing Phase 2 ...
